DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, 524, 526, and 558

New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

Display Date 1-30-03

Publication Date 1-31-03

Certifier R. EDESMA

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 25 approved new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) from Bimeda, Inc., to Cross Vetpharm Group Ltd.

DATES: This rule is effective [insert date of publication in the **Federal Register**].

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967; e-mail: dnewkirk@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Bimeda, Inc., 291 Forest Prairie Rd., LeSueur, MN 56058, has informed FDA that it has transferred ownership of, and all rights and interest in, the following 25 approved NADAs and ANADAs to Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland.

NADA Number	Trade Name
010-092	GALLIMYCIN 50
010–346	COMBUTHAL Powder
012–123	ERYTHRO-100, -200; GALLIMYCIN Injectable
035–157	GALLIMYCIN 100; GALLIMYCIN 500
035–455	ERYTHRO-36 Dry; GALLIMYCIN-36 Dry
035-456	GALLIMYCIN-36 Sterile
038–241	ERYTHRO (High Lev)/Zoalene Plus Arsanilic Acid

NFRI

NADA Number Comment Comment Name Comment Comment Number Comment Comment Name Comment Commen		
038–624 PRO-GALLIMYCIN–10 038–661 SPECTAM Water Soluble Concentrate 041–955 Erythromycin Medicated Premix 044–756 TEVCODYNE 055–059 TEVCOCIN Tablets 093–515 SPECTAM Tablets 095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP		Trade Name
038–661 SPECTAM Water Soluble Concentrate 041–955 Erythromycin Medicated Premix 044–756 TEVCODYNE 055–059 TEVCOCIN Tablets 093–515 SPECTAM Tablets 095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP	038-242	ERYTHRO (Low Lev)/Amp Plus Etho
centrate 041–955 Erythromycin Medicated Premix 044–756 TEVCODYNE 055–059 TEVCOCIN Tablets 093–515 SPECTAM Tablets 095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	038-624	PRO-GALLIMYCIN-10
044–756 TEVCODYNE 055–059 TEVCOCIN Tablets 093–515 SPECTAM Tablets 095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	038–661	
055–059 TEVCOCIN Tablets 093–515 SPECTAM Tablets 095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	041-955	Erythromycin Medicated Premix
093–515 SPECTAM Tablets 095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	044-756	TEVCODYNE
095–218 Dexamethasone Tablets, 0.25 mg 100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	055059	TEVCOCIN Tablets
100–128 Supersweet Medipak TYLAN 10 101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	093–515	SPECTAM Tablets
101–690 ERYTHRO–100 Injection 107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	095-218	Dexamethasone Tablets, 0.25 mg
107–506 CARBAM Tablets 118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	100–128	Supersweet Medipak TYLAN 10
118–032 CARBAM PALATABS 118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	101–690	ERYTHRO-100 Injection
118–979 BUTATRON Gel 120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	107–506	CARBAM Tablets
120–615 SUSTAIN III Bolus 126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	118-032	CARBAM PALATABS
126–504 Nitrofurazone Ointment 200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	118–979	BUTATRON Gel
200–050 Neomycin 325 Soluble Powder 200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	120-615	SUSTAIN III Bolus
200–103 Penicillin G Potassium, USP 200–144 Oxytetracycline HCl Soluble Powder;	126-504	Nitrofurazone Ointment
200–144 Oxytetracycline HCl Soluble Powder;	200-050	Neomycin 325 Soluble Powder
	200–103	Penicillin G Potassium, USP
	200–144	

Accordingly, the agency is amending the regulations in 21 CFR 520.390a, 520.540b, 520.622a, 520.823, 520.1484, 520.1660d, 520.1696b, 520.1720a, 520.1720d, 520.2123a, 520.2123b, 520.2260b, 522.820, 522.2444b, 524.1580b, 526.820, 558.248, and 558.625 to reflect the transfer of ownership.

Following this change of sponsorship, Bimeda, Inc., is no longer the sponsor of any approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Bimeda, Inc.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520, 522, 524, and 526

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, 526, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

2. Section 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications is amended in the table in paragraph (c)(1) by removing the entry for "Bimeda, Inc." and in the table in paragraph (c)(2) by removing the entry for "061133".

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 520.390a [Amended]

4. Section 520.390a *Chloramphenicol tablets* is amended in paragraph (b)(2) by removing "061133" and by adding in its place "061623".

§ 520.540b [Amended]

5. Section 520.540b *Dexamethasone tablets and boluses* is amended in paragraph (b)(2) by removing "061133" and by adding in its place "061623".

§ 520.622a [Amended]

6. Section 520.622a *Diethylcarbamazine citrate tablets* is amended in paragraph (a)(3) by removing "061133" and by adding in its place "061623".

§ 520.823 [Amended]

7. Section 520.823 *Erythromycin phosphate* is amended in paragraphs (b) by removing "061133" and by adding in its place "061623".

§ 520.1484 [Amended]

8. Section 520.1484 Neomycin sulfate soluble powder is amended in paragraph (b)(2) by removing "061133" and by adding in its place "061623".

§ 520.1660d [Amended]

9. Section 520.1660d Oxytetracycline hydrochloride soluble powder is amended in paragraph (b)(7) by removing "061133" and by adding in its place "061623".

§ 520.1696b [Amended]

10. Section 520.1696b *Penicillin G potassium in drinking water* is amended in paragraph (b) by removing "061133" and by adding in its place "061623".

§520.1720a [Amended]

11. Section 520.1720a *Phenylbutazone tablets and boluses* is amended in paragraph (b)(3) by removing "061133" and by adding in its place "061623".

§520.1720d [Amended]

12. Section 520.1720d *Phenylbutazone gel* is amended in paragraph (b) by removing "061133" and by adding in its place "No. 061623".

§520.2123a [Amended]

13. Section 520.2123a Spectinomycin dihydrochloride pentahydrate tablets is amended in paragraph (b) by removing "061133" and by adding in its place "061623".

§ 520.2123b [Amended]

14. Section 520.2123b Spectinomycin dihydrochloride pentahydrate soluble powder is amended in paragraph (b) by removing "061133" and by adding in its place "061623".

§ 520.2260b [Amended]

15. Section 520.2260b Sulfamethazine sustained-release boluses is amended in paragraphs (c)(1) and (e)(1) by removing "061133" and by adding in its place "061623".

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

16. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 522.820 [Amended]

17. Section 522.820 *Erythromycin injection* is amended in paragraph (a) by removing "061133" and by adding in its place "No. 061623".

§ 522.2444b [Amended]

18. Section 522.444b Sodium thiopental, sodium pentobarbital for injection is amended in paragraph (b) by removing "061133" and by adding in its place "061623".

ofe Vinant 6

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

19. The authority citation for 21 CFR part 524 continues to read as follows: Authority: 21 U.S.C. 360b.

§ 524.1580b [Amended]

20. Section 524.1580b *Nitrofurazone ointment* is amended in paragraph (b) by removing "061133" and by adding in its place "061623".

PART 526—INTRAMAMMARY DOSAGE FORM NEW ANIMAL DRUGS

21. The authority citation for 21 CFR part 526 continues to read as follows: Authority: 21 U.S.C. 360b.

§ 526.820 [Amended]

22. Section 526.820 *Erythromycin* is amended in paragraph (b) by removing "061133" and by adding in its place "061623".

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

23. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.248 [Amended]

24. Section 558.248 Erythromycin thiocyanate is amended paragraphs (a)(1) and (a)(2) by removing "061133" and by adding in its place "061623"; and in the table in paragraph (d)(1) in the "Sponsor" column by removing "061133" wherever it appears and by adding in its place "061623".

§ 558.625 [Amended]

25. Section 558.625 *Tylosin* is amended in the table in paragraph (b)(39) by removing "061133" and by adding in its place "061623".

Steven D. Vaughn, 0

Director,

Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 03-????? Filed ??-??-03; 8:45 am]

BILLING CODE 4160-01-S

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL